Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1.

Künzli K, Favre B, Chofflon M, Borradori L.

Exp Dermatol. 2016 Jan;25(1):10-6. doi: 10.1111/exd.12877. Epub 2015 Dec 4. Review.

PMID:
26479498
2.

Dual-task assessment in natalizumab-treated multiple sclerosis patients.

Allali G, Laidet M, Assal F, Chofflon M, Armand S, Lalive PH.

Eur Neurol. 2014;71(5-6):247-51. doi: 10.1159/000357217. Epub 2014 Feb 1.

PMID:
24503719
3.

Illustrating the relevance of updated diagnostic criteria for sporadic Creutzfeldt-Jakob disease: a teaching neurocase.

Kamtchum Tatuene J, Vargas MI, Burkhardt K, Chofflon M.

BMJ Case Rep. 2013 Aug 28;2013. pii: bcr2013010061. doi: 10.1136/bcr-2013-010061.

4.

Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672].

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Vander-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2013 May;19(6):831-2. doi: 10.1177/1352458513485150. No abstract available.

PMID:
23658240
5.

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2012 Dec;18(12):1721-36. doi: 10.1177/1352458512441381. Epub 2012 Mar 28.

6.

Adapted timed up and go: a rapid clinical test to assess gait and cognition in multiple sclerosis.

Allali G, Laidet M, Assal F, Beauchet O, Chofflon M, Armand S, Lalive PH.

Eur Neurol. 2012;67(2):116-20. doi: 10.1159/000334394. Epub 2012 Jan 10.

PMID:
22236807
7.

Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.

Abbas M, Lalive PH, Chofflon M, Simon HU, Chizzolini C, Ribi C.

Neurology. 2011 Oct 18;77(16):1561-4. doi: 10.1212/WNL.0b013e318233b391. Epub 2011 Oct 5.

PMID:
21975205
8.

Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.

Weber MS, Benkhoucha M, Lehmann-Horn K, Hertzenberg D, Sellner J, Santiago-Raber ML, Chofflon M, Hemmer B, Zamvil SS, Lalive PH.

PLoS One. 2010 Dec 30;5(12):e16009. doi: 10.1371/journal.pone.0016009.

9.

Magnetic resonance imaging in multiple sclerosis.

Haller S, Pereira VM, Lalive PH, Chofflon M, Vargas MI, Lövblad KO.

Top Magn Reson Imaging. 2009 Dec;20(6):313-23. doi: 10.1097/RMR.0b013e318207a390. Review.

PMID:
21187724
10.

Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells.

Benkhoucha M, Santiago-Raber ML, Schneiter G, Chofflon M, Funakoshi H, Nakamura T, Lalive PH.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6424-9. doi: 10.1073/pnas.0912437107. Epub 2010 Mar 23.

11.

[Inflammatory neuropathies and multineuritis].

Kuntzer T, Chofflon M.

Rev Med Suisse. 2009 Dec 2;5(228):2469-73. Review. French.

PMID:
20088123
12.

Increasing the diagnostic value of evoked potentials in multiple sclerosis by quantitative topographic analysis of multichannel recordings.

Lascano AM, Brodbeck V, Lalive PH, Chofflon M, Seeck M, Michel CM.

J Clin Neurophysiol. 2009 Oct;26(5):316-25. doi: 10.1097/WNP.0b013e3181baac00.

PMID:
19752740
13.

[Autoantibodies in neurological diseases: clinical implications].

Lalive PH, Chofflon M, Du Pasquier RA, Burkhard PR.

Rev Med Suisse. 2009 Apr 29;5(201):942-4, 946-8, 950. French.

PMID:
19476056
14.

[Multiple sclerosis and pregnancy].

Chofflon M, Lalive PH.

Rev Med Suisse. 2009 Apr 29;5(201):936, 938-40. French.

PMID:
19476055
15.

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil SS, Lalive PH.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4355-9. doi: 10.1073/pnas.0812183106. Epub 2009 Mar 2.

16.

[The painful multiple sclerosis].

Chofflon M, Lalive PH.

Rev Med Suisse. 2008 Jun 18;4(162):1491-2, 1494-7. French.

PMID:
18649595
17.

Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.

Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M.

J Neuroimmunol. 2008 Jul 15;197(2):147-51. doi: 10.1016/j.jneuroim.2008.04.033. Epub 2008 Jun 13.

PMID:
18555540
18.

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.

Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS.

Curr Med Res Opin. 2007 Nov;23(11):2823-32. Review.

PMID:
17908370
19.

[Neuromyelitis optica/Devic's syndrome: new perspectives].

Lalive PH, Perrin L, Chofflon M.

Rev Med Suisse. 2007 Apr 11;3(106):950-5. Review. French.

PMID:
17575971
20.

Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.

Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, Gougeon ML, Chofflon M, Lalive PH.

J Neuroimmunol. 2007 Apr;185(1-2):123-9. Epub 2007 Feb 15.

PMID:
17306890
21.

Cerebrospinal fluid anti-SSA autoantibodies in primary Sjogren's syndrome with central nervous system involvement.

Mégevand P, Chizzolini C, Chofflon M, Roux-Lombard P, Lalive PH, Picard F.

Eur Neurol. 2007;57(3):166-71. Epub 2007 Jan 10. Erratum in: Eur Neurol. 2007 Mar;57(3):190A.

PMID:
17213724
22.

[Immunity and neurodegeneration: new concepts in multiple sclerosis].

Lalive PH, Schluep M, Chofflon M, Du Pasquier R.

Rev Med Suisse. 2006 May 3;2(64):1166-8, 1170. Review. French.

PMID:
16734188
23.

A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.

Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A; International Working Group for Treatment Optimization in MS.

Eur J Neurol. 2006 Jan;13(1):61-71. Review.

PMID:
16420394
25.

[Immunomodulatory/suppressive treatments in neurology].

Schluep M, Chofflon M, Kuntzer T, Du Pasquier R.

Rev Med Suisse. 2005 May 4;1(18):1229-32. Review. French.

PMID:
15977712
26.

Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?

Laffitte E, Burkhard PR, Fontao L, Jaunin F, Saurat JH, Chofflon M, Borradori L.

Br J Dermatol. 2005 Mar;152(3):537-40.

PMID:
15787824
27.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group.

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
28.

[Various infective diseases of the nervous system].

Vokatch N, Chofflon M.

Rev Med Suisse Romande. 2003 Jan;123(1):69-74. French.

PMID:
15095730
29.

[Multiple sclerosis: current therapeutic strategies].

Chofflon M.

Rev Med Suisse Romande. 2003 Jan;123(1):27-32. Review. French. No abstract available.

PMID:
15095724
30.

TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapse.

Lalive PH, Burkhard PR, Chofflon M.

Behav Neurosci. 2002 Dec;116(6):1093-7.

PMID:
12492308
31.

Isolated unilateral adduction deficit and ptosis as the presenting features of chronic inflammatory demyelinating polyradiculoneuropathy.

Pieh C, Rossillion B, Heritier-Barras AC, Chofflon M, Landis T, Safran AB.

J Neuroophthalmol. 2002 Jun;22(2):92-4.

PMID:
12131466
32.

Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.

Chofflon M, Ben-Amor AF.

Clin Neurol Neurosurg. 2002 Jul;104(3):244-8. Review. No abstract available.

PMID:
12127662
33.

Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Fellay B, Chofflon M, Juillard C, Paunier AM, Landis T, Roth S, Gougeon ML.

Immunology. 2001 Dec;104(4):383-91.

34.

Internal ophthalmoplegia as a presenting sign of herpes zoster ophthalmicus.

Assal F, Frank HG, von Gunten S, Chofflon M, Safran AB.

Eur Neurol. 2001;45(3):189-90. No abstract available.

PMID:
11306868
35.

Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials.

Chofflon M.

Eur J Neurol. 2000 Jul;7(4):369-80. Review. Erratum in: Eur J Neurol 2000 Sep;7(5):593.

PMID:
10971595
36.

Diaphragmatic paralysis with monoclonal gammopathy and antiganglioside GM1 antibodies.

Dozier CE, Sztajzel R, Kohler A, Chofflon M, Magistris MR, Rohr-Le Floch J.

Neurology. 1999 May 12;52(8):1715-6. No abstract available.

PMID:
10331712
37.

Cerebrospinal fluid in acute peripheral facial palsy.

Kohler A, Chofflon M, Sztajzel R, Magistris MR.

J Neurol. 1999 Mar;246(3):165-9.

PMID:
10323312
38.

[Brown-Vialetto-Van Laere syndrome: a case with anti-ganglioside GM1 antibodies and literature review].

Sztajzel R, Kohler A, Reichart M, Djientcheu VP, Chofflon M, Magistris MR.

Rev Neurol (Paris). 1998 Jan;154(1):51-4. Review. French.

PMID:
9773026
39.

Monitoring multiple sclerosis course and activity with TNF-alpha.

Chofflon M, Fellay B.

Mult Scler. 1998 Jun;4(3):188-92. No abstract available.

PMID:
9762672
40.

Corticosteroid-responsive postmalaria encephalopathy characterized by motor aphasia, myoclonus, and postural tremor.

Schnorf H, Diserens K, Schnyder H, Chofflon M, Loutan L, Chaves V, Landis T.

Arch Neurol. 1998 Mar;55(3):417-20.

PMID:
9520017
41.

Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis.

Chofflon M, Roth S, Juillard C, Paunier AM, Juillard P, Degroote D, Grau GE.

Eur Cytokine Netw. 1997 Sep;8(3):253-7.

42.
43.

Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity.

Lou J, Chofflon M, Juillard C, Donati Y, Mili N, Siegrist CA, Grau GE.

Neuroreport. 1997 Feb 10;8(3):629-33.

PMID:
9106736
44.

[Isolated peripheral facial paralysis and HIV infection: 7 cases].

Kohler A, Burkhard P, Magistris MR, Chofflon M.

Rev Neurol (Paris). 1995 May;151(5):332-7. Review. French.

PMID:
7481391
45.

Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.

Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, Cattaneo R, Zambruni A, Troianello B, Chofflon M, et al.

Springer Semin Immunopathol. 1994;16(2-3):313-21.

PMID:
7716711
46.

Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis.

Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE.

Eur Cytokine Netw. 1992 Nov-Dec;3(6):523-31.

PMID:
1296800
47.

[HTLV-I/II in Switzerland: apropos of 4 case reports].

de Saussure P, Chofflon M, Pugin P, Bierens de Hahn D, Perrin L.

Schweiz Med Wochenschr. 1991 Nov 30;121(48):1761-6. Review. French.

PMID:
1684064
48.

Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera.

Adams D, Kuntzer T, Burger D, Chofflon M, Magistris MR, Regli F, Steck AJ.

J Neuroimmunol. 1991 Jun;32(3):223-30.

PMID:
2033117
49.

Correlation between in vitro cytokine production and clinical evolution of multiple sclerosis patients.

Chofflon M, Juillard C, Gauthier G, Grau GE.

Schweiz Arch Neurol Psychiatr (1985). 1991;142(2):107-12.

PMID:
1710376
50.

Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis.

Hafler DA, Chofflon M, Kurt-Jones E, Weiner HL.

Clin Immunol Immunopathol. 1991 Jan;58(1):115-25.

PMID:
1670583

Supplemental Content

Loading ...
Support Center